CN104704371B - 新的由d3衍生的d‑对映体肽及其用途 - Google Patents

新的由d3衍生的d‑对映体肽及其用途 Download PDF

Info

Publication number
CN104704371B
CN104704371B CN201380047981.9A CN201380047981A CN104704371B CN 104704371 B CN104704371 B CN 104704371B CN 201380047981 A CN201380047981 A CN 201380047981A CN 104704371 B CN104704371 B CN 104704371B
Authority
CN
China
Prior art keywords
peptide
seq
peptides
oligomers
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380047981.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN104704371A (zh
Inventor
D·威尔伯德
O·布兰恩尔
S·A·方克
L·内格尔斯特格尔
D·巴尔蒂尼克
A·N·克勒恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Priaved Ltd
Original Assignee
Forschungszentrum Juelich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forschungszentrum Juelich GmbH filed Critical Forschungszentrum Juelich GmbH
Priority to CN201710944015.7A priority Critical patent/CN107556375A/zh
Publication of CN104704371A publication Critical patent/CN104704371A/zh
Application granted granted Critical
Publication of CN104704371B publication Critical patent/CN104704371B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2410/00—Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
CN201380047981.9A 2012-09-14 2013-09-13 新的由d3衍生的d‑对映体肽及其用途 Active CN104704371B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710944015.7A CN107556375A (zh) 2012-09-14 2013-09-13 新的由d3衍生的d‑对映体肽及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102012108598.6 2012-09-14
DE102012108598.6A DE102012108598A1 (de) 2012-09-14 2012-09-14 Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung
PCT/EP2013/068992 WO2014041115A2 (de) 2012-09-14 2013-09-13 Neue, von d3 abgeleitete d-enantiomere peptide und deren verwendung

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710944015.7A Division CN107556375A (zh) 2012-09-14 2013-09-13 新的由d3衍生的d‑对映体肽及其用途

Publications (2)

Publication Number Publication Date
CN104704371A CN104704371A (zh) 2015-06-10
CN104704371B true CN104704371B (zh) 2017-11-07

Family

ID=49354628

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380047981.9A Active CN104704371B (zh) 2012-09-14 2013-09-13 新的由d3衍生的d‑对映体肽及其用途
CN201710944015.7A Pending CN107556375A (zh) 2012-09-14 2013-09-13 新的由d3衍生的d‑对映体肽及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710944015.7A Pending CN107556375A (zh) 2012-09-14 2013-09-13 新的由d3衍生的d‑对映体肽及其用途

Country Status (9)

Country Link
US (3) US20150307552A1 (https=)
EP (2) EP2895867B1 (https=)
JP (2) JP6345670B2 (https=)
CN (2) CN104704371B (https=)
DE (1) DE102012108598A1 (https=)
DK (2) DK3346273T5 (https=)
ES (2) ES2938773T3 (https=)
PL (1) PL3346273T3 (https=)
WO (1) WO2014041115A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012108598A1 (de) * 2012-09-14 2014-04-10 Forschungszentrum Jülich GmbH Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung
DE102015003676A1 (de) 2015-03-20 2016-09-22 Forschungszentrum Jülich GmbH Fachbereich Patente Spezifisch A-Beta Spezies bindende Peptide für die Therapie und/oder die Diagnose der Alzheimerschen Demenz
DE102015003503A1 (de) * 2015-03-20 2016-09-22 Forschungszentrum Jülich GmbH Spezifisch Amyloid-Beta bindende Peptide und deren Verwendung für die Therapie und Diagnose der Alzheimerschen Demenz
DE102016125645A1 (de) * 2016-12-23 2018-06-28 Forschungszentrum Jülich GmbH D-enantiomere Peptide zur Therapie von chronischem und neuropathischem Schmerz
EP3691670A4 (en) * 2017-10-02 2021-08-04 Cedars-Sinai Medical Center METHODS AND COMPOSITIONS FOR EFFECTIVE ADMINISTRATION ACROSS MULTIPLE BIOLOGICAL BARRIERS
DE102021121435A1 (de) * 2021-08-18 2023-02-23 Priavoid Gmbh Aß-BINDENDE SUBSTANZEN

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081505A2 (de) * 2001-04-06 2002-10-17 imb Institut für molekulare Biotechnologie e.V. Peptid zur diagnose und therapie der alzheimer-demenz

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE355374T1 (de) * 2000-11-27 2006-03-15 Praecis Pharm Inc Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
JPWO2002081515A1 (ja) * 2001-04-03 2004-07-29 協和醗酵工業株式会社 インスリン様増殖因子結合蛋白質
US20050158306A1 (en) * 2004-01-16 2005-07-21 Halikas James A. Treatment for neuro-degenerative disease by a blood cleansing system using monoclonal antibodies
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
US20070092508A1 (en) * 2005-10-21 2007-04-26 Recombiant Technologies, Llc Detoxification depot for Alzheimer's disease
WO2010062570A2 (en) * 2008-10-27 2010-06-03 Recombinant Technologies Llc COMPOSITIONS COMPRISING CAPTURE PEPTIDES FOR A β-AMYLOID PEPTIDE
DE102008037564A1 (de) * 2008-11-19 2010-05-20 Forschungszentrum Jülich GmbH Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden
DE102010017130B4 (de) 2010-05-28 2018-11-29 Forschungszentrum Jülich GmbH Hybrid-Verbindung, deren Verwendung und Verfahren zu deren Herstellung
EP2834644B1 (de) * 2012-04-05 2019-08-21 Forschungszentrum Jülich GmbH Polymere, enthaltend multivalente amyloid-beta-bindende d-peptide und deren verwendung
DE102012108598A1 (de) * 2012-09-14 2014-04-10 Forschungszentrum Jülich GmbH Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung
DK2834643T3 (da) * 2012-04-05 2020-02-03 Forschungszentrum Juelich Gmbh Fremgangsmåde til behandling af blod, blodprodukter og organer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081505A2 (de) * 2001-04-06 2002-10-17 imb Institut für molekulare Biotechnologie e.V. Peptid zur diagnose und therapie der alzheimer-demenz

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Differently selected D-enantionmeric peptides act on different Aβ species.;Dirk Bartnik et. al.;《Rejuvenation Research》;20101231;第13卷;第202-203页 *
In vitro and in vivo staining characteristics of small fluorescent, Aβ42-binding D-enantiomeric peptides in transgenic AD mouse models.;Thomas van Groen et. al.;《ChemMedChem》;20091231;第4卷;第277页，第281页 *
Multiple-peptide conjugates for binding β-amyloid plaques of Alzheimers disease.;Guobao Zhang et.al.;《Bioconjugate Chem》;20031231;第14卷;第86-92页 *
Oral treatment with the D-enantiomeric peptide D3 improves the pathology and behavior of Alzheimers disease transgenic mice.;Susanne Aileen Funke et. al.;《ACS Chem Neurosci》;20100802;第1卷;图1，图2，第642页，第646页右侧栏第3段 *
Reduction of Alzheimer s disease amyloid plaque load in transgenic mice by D3, a D-enantiomeric peptide identified by mirror image phage display.;Thomas van Groen et. al.;《ChemMedChem》;20081231;第3卷;图1，图3，第1848页左侧栏最后一段，第1851页右侧栏，第1852页左侧栏最后一段 *

Also Published As

Publication number Publication date
US20190085030A1 (en) 2019-03-21
US20150307552A1 (en) 2015-10-29
JP6345670B2 (ja) 2018-06-20
ES2768264T3 (es) 2020-06-22
WO2014041115A2 (de) 2014-03-20
DE102012108598A1 (de) 2014-04-10
EP3346273B1 (de) 2023-01-04
WO2014041115A3 (de) 2014-06-26
DK3346273T5 (da) 2024-09-30
PL3346273T3 (pl) 2023-04-11
CN107556375A (zh) 2018-01-09
JP2018141008A (ja) 2018-09-13
US10889618B2 (en) 2021-01-12
JP6611858B2 (ja) 2019-11-27
JP2015531348A (ja) 2015-11-02
EP2895867B1 (de) 2019-10-23
EP3346273A1 (de) 2018-07-11
EP3346273A8 (de) 2018-08-29
ES2938773T3 (es) 2023-04-14
EP2895867A2 (de) 2015-07-22
DK3346273T3 (da) 2023-02-27
DK2895867T3 (da) 2020-02-03
US10167318B2 (en) 2019-01-01
US20170313744A1 (en) 2017-11-02
CN104704371A (zh) 2015-06-10

Similar Documents

Publication Publication Date Title
US10889618B2 (en) D-enantiomeric peptides derived from D3 and use thereof
JP6861684B2 (ja) 多価アミロイドβに結合するＤ−ペプチド含有ポリマー及びその使用
JP6997160B2 (ja) 血液、血液生産物及び器官を処置する方法
US20200317734A1 (en) Amyloid-beta-binding peptides and the use thereof for the treatment and diagnosis of alzheimer's disease
JP2020023510A (ja) アミロイドベータ結合性環状ペプチドおよびその使用
JP6714610B2 (ja) アルツハイマー型認知症の治療および／または診断のための特定のａ−ベータ種に結合するペプチド
CA3071634C (en) Antibody binding active alpha-synuclein
CA3071634A1 (en) Antibody binding active alpha-synuclein

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20220114

Address after: Germany to leach

Patentee after: Priaved Ltd.

Address before: Juelich, Germany

Patentee before: FORSCHUNGSZENTRUM JULICH GmbH